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Central  nervous  system  (CNS)  thrombotic  events  are  a  well-known  complication  of  acute
lymphoblastic leukemia (ALL) induction therapy, especially with treatments including L-asparaginase
(L-ASP). Data on risk factors and clinical evolution is still lacking in adult patients. We report on the
clinical evolution of 22 CNS venous thrombosis cases occurring in 708 adults treated for ALL or
lymphoblastic lymphoma (LL) with the Group for Research on Adult Acute Lymphoblastic Leukemia
(GRAALL)-induction protocol, which included eight L-ASP (6000 IU/m²) infusions. The prevalence
of CNS thrombosis was 3.1%. CNS thrombosis occurred after a median of 18 days (range: 11-31)
when  patients  had  received  a  median  of  three  L-ASP injections  (range:  2-7).  Patients  with  CNS
thrombosis exhibited a median antithrombin (AT) nadir of 47.5% (range: 36%-67%) at Day 17 (range:
D3-D28), and 95% of them exhibited AT levels lower than 60%. There were no evident increase in
hereditary thrombotic risk factors prevalence, and thrombosis occurred despite heparin prophylaxis
which was performed in 90% of patients. Acquired AT deficiency was frequently detected in patients
with L-ASP-based therapy, and patients with CNS thrombosis received AT prophylaxis (45%) less
frequently than patients without CNS thrombosis (83%), p= .0002). CNS thrombosis was lethal in 5%
of patients,  while 20% had persistent  sequelae.  One patient  received all  planned L-ASP infusions
without recurrence of CNS thrombotic whereas L-ASP injections were discontinued in 20 patients
during the management of thrombosis without a significant impact on overall survival (p= .4). 
Introduction
Venous thrombosis is a well-known complication of induction chemotherapy for acute lymphoblastic
leukemia (ALL).1-4 Thrombosis occurred during induction therapy at a rate of 4.8% in 1280 children
included in 17 prospective studies, and of 5.9% in 323 adults included in 13 prospective studies. 2,3
Central  nervous system (CNS) thrombosis  is  the  most  tragic thrombotic event  (TE).  Although its
occurrence during ALL induction therapy is  well-documented,  little  data is  available regarding its
clinical presentation, risk factors, and specific evolution.4 L-asparaginase (L-ASP) is one of the major
drugs used in ALL treatment.5-7 This enzyme induces a relative deficiency in asparagine, which is
essential for leukemic cell growth, thus leading to the death of human lymphoblasts. Because this drug
inhibits  the  hepatic  synthesis  of  L-asparagine-dependent  hemostatic  proteins,  particularly  plasma
antithrombin (AT)8,9, venous thrombosis, is highly associated with the administration of L-ASP during
induction  therapy  in  both  children10,11 and  adults.12 We  therefore  sought  to  explore  this  serious
complication, and to analyze the impact of L-ASP on its incidence by reviewing every case of CNS
venous  thrombosis  that  occurred  during  induction  chemotherapy  of  adult  patients  with  ALL or
lymphoblastic  lymphoma  (LL)  included  in  the  LL0313,  GRAALL 200314,  and  200515 trials,  with
special attention to concomitant drugs and events. 
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Abstract
Design and Methods
Patients
The occurrence of CNS thrombosis in patients included from April 2004 to July 2011 in the GRAALL
2003,  GRAALL  2005,  and  LL03  protocols  was  prospectively  reported  to  the  GRAALL  data
management center  as serious adverse events.  Data  from every patient  with CNS thrombosis was
reviewed  retrospectively  including  risk  factor,  clinical  presentation,  coagulation  data,  thrombosis
prophylaxis, and treatment. Clinical characteristics of patients with CNS thrombosis were compared to
those without CNS thrombosis included in the GRAALL 2003 (n=225), GRAALL 2005 (n=347), and
LL03 protocols (n=136). Compliance to thrombosis prophylaxis recommendations were not recorded
and general or hereditary thrombosis risk factor were not systematically assessed and can not therefore
be analyzed for patients without thrombosis. Patients without CNS thrombosis but with thrombosis
occurring at other sites during induction were not included in the control group.
Chemotherapy regimen
The GRAALL 2003 evaluated the feasibility of a pediatric-based treatment in young adults (18-59
years old) with Philadelphia chromosome (Ph1)-negative ALL in a multicenter, prospective, phase II
trial. GRAALL 2005 is a randomized trial evaluating the impact of high-dose cyclophosphamide and
rituximab included in the induction therapy in patients with CD20+ ALL. The LL03 study was a
multicenter, phase II trial evaluating the safety and effectiveness of intensive chemotherapy as used for
the treatment of ALL in young adult patients with LL. In these three studies, induction therapy was
very similar. All patients received a prephase with prednisone (60 mg/m²/day) for 7 to 10 days, then
induction therapy combining daunorubicin (50 mg/m²/injection on Days 1-3, then 30 mg/m² on Days
15  and  16),  weekly  intravenous  vincristin  (2  mg/injection),  eight  L-ASP (6000  UI/m²/injection)
intravenous  injections  and  2  weeks  of  daily  oral  prednisone  (60  mg/m²/day).  Cyclophosphamide
(CPM) was  administered at  750 mg/m²  on Day 1,  then at  300 mg/m²/12h on Days  15-17 in  the
GRALL 2003 and in the intensified arm of the GRAALL 2005 studies (“HyperC arm”); at 750 mg/m²
on Day 15 in the standard arm of the GRAALL 2005 study and at 500 mg/m²/12h on Days 15 and 16
in  the  LL03  study.  In  order  to  prevent  interaction  with  other  drugs,  L-ASP was  administrated
intravenously (IV) on Days 8, 10, and 12 during the first part of induction, and then on Days 20, 22,
24,  26,  and  28,  after  the  reintroduction  of  daunorubicin,  cyclophosphamide  and  vincristin.  In
accordance with standard recommendations,  Escherichia coli L-ASP (Kidrolase®) was switched for
Erwinia chrysanthemi L-ASP (Erwiniase®) 12000 UI/m²/IV injections in case of allergic reactions.
CNS prophylaxis included methotrexate 15 mg intra-thecal injections during the prephase and triple
intra-thecal injections (methotrexate 15 mg, aracytine 40 mg and depomedrol 40 mg) at days 1 and 8.
Patients  in  complete  remission  (CR)  received  a  consolidation  course  in  quick  succession  of  six
alternating  blocks  with  high-dose  methotrexate,  high-dose  aracytine,  and  cyclophosphamide  in
conjunction with low doses of other cytotoxic drugs. In the three protocols, all patients in persistent
CR for whom allogeneic stem cell transplantation was not indicated in first CR received a standard or
HyperC late  intensification with the  same drugs used during the induction course,  followed by a
repetition  of  three  consolidation  blocks.  In  addition  to  the  neuro-meningeal  prophylaxis  during
prephase and induction, patients received 3 additional intra-thecal injections and cerebral irradiation
(18Gy)  at  the  end  of  consolidation  (GRAALL 2003  and  GRAALL 2005),  or  at  the  end  of  late
intensification  (LL03).  Then,  patients  proceeded to  maintenance  therapy which  included monthly
vincristin infusions and long-term oral methotrexate and 6-mercaptopurine administration. 
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Thrombosis prophylaxis and diagnosis
Recommendations for thrombosis prophylaxis were based on CAPELAL study results16: Antithrombin
(AT) and fibrinogen levels were evaluated prospectively before each L-ASP infusion (Days 8, 10, and
12, and then every other day from Day 20 to 28).  No other coagulation factor was systematically
evaluated. Fresh frozen plasma or fibrinogen concentrates were recommended if fibrinogen levels fell
below 0.5 g/L, platelet transfusion support was recommended for platelets below 20.10 9/L and AT
concentrate  substitution therapy (Aclotine®, 25 U/kg) was recommended in order to maintain AT
levels above 60%. AT levels were re-evaluated the day after AT infusion. L-ASP were re-administrated
after  correcting  the  acquired  deficiency  in  AT.  Recommendations  also  included  the  use  of
unfractionated  heparin  (UFH)  at  100  UI/Kg/day in  continuous  infusion  or  low molecular  weight
heparin (LMWH) at prophylactic doses in subcutaneous injection during induction, without particular
monitoring. Heparin prophylaxis was interrupted when platelets were below 20.10 9/L and resumed
after platelet transfusion. 
Cerebral imaging was performed in case of otherwise inexplicable neurological symptoms, including
headaches:  CNS  venous  thrombosis  was  confirmed  by  computed  tomography  [CT]  or  magnetic
resonance imaging [MRI] showing the sino-venous thrombus. Cerebral angiography was performed in
case  of  persisting  doubt.  The  presence  and  nature  of  parenchymal  lesion  was  reported,  such  as
hemorrhagic infarcts or brain oedema. The localisation of thrombosis was classified as occurring in
lateral, longitudinal, sagittal, transversal or cortical veins. 
Statistical analysis
Statistical analyses were performed with the use of the GraphPad PRISM version 6.0e program. For
univariate analysis, we performed Mann-Whitney nonparametric tests in case of quantitative variables,
and a CHI2 test to compare percentages. To compare survival data, we performed a log-rank test. A p-
value <0.05 was considered statistically significant.
Results
Prevalence
From April 2004 to July 2011, 572 patients were included in the two GRAALL protocols, as well as
136 patients in the LL03 protocol. CNS thrombosis was reported in 22 of these 708 patients (3.1%), in
2.8% of  ALL patients  (16/572)  and  in  4.4% of  LL patients  (6/136).  In  patients  included  in  the
GRAALL 2005 study, the prevalence of thrombotic events during induction was 9.5% (33/347): 36%
were CNS thromboses,  30% lower limb thromboses,  18% upper limb thromboses,  9% pulmonary
embolisms, 3% portal system thrombosis, and only 3% arterial thromboses.
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Patient characteristics
CNS thrombosis occurred in two patients prior to L-ASP infusions (2/708) and in 20/708 patients
during or after L-ASP during induction therapy, i-e respectively 0.28% versus 2.8% (p= .0001). The 2
patients with CNS thrombosis occurring before L-ASP infusions are not included in the subsequent
analysis but are detailed at the end of the results section. Of the 20 patients with CNS thrombosis
occurring during L-ASP treatment, the median age was 29 (range: 18-50 years), and 75% were male
(Table I). CNS thrombosis was more frequent in T cell-ALL (13/262, 5%) than in B cell-ALL (7/394,
1.8%)  (p= .034). Poor-risk prognostic factors, such as steroid-resistance, early chemo-resistance, as
well  as  failure  to  achieve  complete  remission,  were  similar  between these  20  patients  and  those
without  CNS  thrombosis  (data  not  shown).  There  was  no  significant  association  between  CNS
thrombosis and hyperleucocytosis (> 30.109/L) or blastic CNS involvement (Table I). The distribution
of karyotype abnormalities was roughly similar to that of patients without CNS thrombosis (data not
shown); abnormalities were observed in more than half of the CNS thrombosis patients (12/20, 60%),
including four poor cytogenetics with one t(1;14), one t(1;19), and two complex karyotypes. None of
the patients with CNS thrombosis had allergic reaction to Escherichia coli L-ASP.
CNS thrombosis
CNS venous thrombosis was identified based on clinical signs and was confirmed by radiological
imaging:  cerebral  CT in 8 patients,  cerebral  MRI in 5 patients,  and both in 9 patients.  The most
common sites of CNS thrombosis included the longitudinal sinus (11), cortical vein (11), lateral sinus
(5), sagittal sinus (4), and transverse (2). Intra-cerebral hemorrhage was associated with thrombosis in
7 patients (35%).  At diagnosis,  CNS clinical  symptoms were headaches (8/20,  40%),  which were
isolated in  2  patients  (10%),  seizures  (13/20,  65%),  which were  isolated in  2  patients  (10%),  or
neurological changes (15/20, 75%) including motor deficits, paresthesias, or visual/ophthalmic signs.
Half of the patients exhibited prodromal symptoms (10/20, 50%), consisting almost exclusively of
headaches (9/10) (Table II). In this cohort, four patients (20%) experienced other venous thrombotic
events during induction, as detailed in Table II.  One patient died 5 days after CNS thrombosis due to
cerebral  hemorrhage associated  with thrombosis.  None  of  the  other  CNS thrombotic  events  were
lethal, but 4 patients (20%) experienced neurological sequelae, recorded as persistent headaches (1
patient), epilepsy (1 patient), and motor or cognitive deficiency (2 patients). 
Thrombotic risk factors
CNS thrombosis occurred from Day 11 through Day 31 (median: Day 18) after starting induction
therapy, after a median of 3 L-ASP injections (range: 2-7) (Tables I and III). AT levels fell under the
60% threshold in almost all patients (95%), with levels falling below 50% in 15/20 (75%) patients.
The median AT nadir was 47.5% (range: 36%-67%) and occurred at Day 17 (range: D3-D28); this was
not significantly different with the median AT nadir of patients without CNS thrombosis (51%, p= .
25). At baseline, median platelet count was 91.109/L (range, 37-465) and median fibrinogen level was
3.3 g/L (range, 1.19-4.81), while when CNS thrombosis occurred, median platelet count was 101.109/L
(range, 19-380) (p= .59) and fibrinogen level was 1.5 g/L (range, 0.8-7) (p= .1) which did not differ
significantly  from  patients  without  CNS  thrombosis  (p=  0,9  and  p=0,15,  Table  I).  Despite
recommendations, prophylactic AT infusions was only performed in 9 patients with CNS thrombosis
(45%), whereas 83.2% of patients without  CNS thrombosis received prophylactic AT concentrates
(p= .0002)  (Tables I and III). Fibrinogen concentrate was infused only once, at Day 9, in a patient
whose CNS thrombosis occurred at Day 19 and Fresh-frozen plasma was infused in 2 patients, 3 and
5
14 days before the occurrence of CNS thrombosis.  Prophylactic anticoagulation does not seem to
protect  from CNS thrombosis,  as it  was performed in 90% of patients with CNS thrombosis and
surprisingly, in only 64.9% of the patients without CNS thrombosis (Tables I and III).
Intra-thecal injections were administered prior to CNS thrombosis in all but 1 patient. CNS thrombosis
occurred after a median of 3 intra-thecal injections (range: 0-3), after a median of 11 days (range: 4-
16) following the most recently received IT (Table II).  In addition, the total number of intra-thecal
injections administrated was higher in patients with CNS thrombosis than in those without (3 vs 2, p< .
0001). Because the GRAALL protocols evaluated CPM dose intensification, we analyzed CPM doses
as a potential thrombosis risk factor. The proportion of patients receiving high-dose CPM was similar
in patients with and without CNS thrombosis (50% vs 45%) (Data not shown). The number of L-ASP
infusions  during  induction  was  lower  in  patients  with  CNS  thrombosis  than  in  patients  without
thrombosis as the interruption of L-ASP infusions was recommended after CNS thrombosis.
None of the 20 patients reported a personal or familial history of thrombosis. Hereditary thrombotic
risk factors (protein S deficiency, protein C deficiency, activated protein C, lupus anticoagulant) were
evaluated at ALL/LL diagnosis according to the GRAALL2005 recommendations or at the time of
thrombosis if not  performed before. Two patients (10%) had been diagnosed as having hereditary
protein S deficiency and heterozygous factor V Leiden mutations were found in 3 patients (15%).
There  were  no  prothrombin  G20210A gene  mutations.  One  patient  was  diagnosed  as  having,
simultaneously, hereditary protein S deficiency, heterozygous factor V Leiden mutation, and a lupus
anticoagulant. None of our patients were taking combined oral contraceptives, as this medication was
stopped before induction therapy in one female patient, and progestin derivatives were administrated
in all five female patients. 
CNS thrombosis management
Of  the  20  patients,  anticoagulant  treatment  was  not  initiated  in  1  patient  presenting  cerebral
hemorrhagic lesions, rapidly resulting in death and 19 were initially treated with UFH or LMWH. The
therapeutic goal level was a target APTT (activated partial thromboplastin time) between 1.5 and 2.
There were no bleeding complications. Therapeutic anticoagulation was maintained for 6 months after
thrombosis, or longer in case of recurrent thrombotic events. During anticoagulation, platelet levels
were  maintained  above  50.109/L  with  platelet  transfusion  support.  Concomitant  surgical  sinus
thrombectomy was performed in 1 patient. No recurrence of CNS thrombosis occurred but despite
therapeutic  anticoagulation,  recurrent  thrombotic  events  occurred  in  4  patients  (20%)  with  1
pulmonary  embolism  (PE),  1  lower  limb  thrombosis,  and  2  concomitant  pulmonary  and  limb
thrombosis  (table  II).  AT concentrates  at  curative  doses  were  administered  in  10  patients  (50%),
specifically in 80% and 33.3% of patients with and without neurological sequelae, respectively. 
Impact on survival
The complete remission (CR) rate was 90% as 1 of the 20 patients died during induction because of
intra-cerebral hemorrhagic complications of the CNS thrombosis and 1 failed to achieved CR at the
end of induction. This is similar to the 90% CR rate obtained in patients without CNS thrombosis
included in the GRAALL 2005 study.15 Relapse occurred in 8 patients with CNS thrombosis.  CNS
thrombosis was associated with a non-significant reduced 3-year overall  survival (55%  vs.  75.9%,
p=0.4) and 3-year disease-free survival (61.3% vs. 79.5%, p=0.18) (Table I, Figure 1).
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CNS thrombosis occurring before L-ASP infusion
CNS thrombosis occurred prior to L-ASP infusion in 2 patients, at Day -5 and Day 2 from induction
chemotherapy, respectively in a 22-year-old woman with B-ALL with normal karyotype who received
oral combined contraceptive prior to ALL therapy and in an obese 28-year-old man with T-LL with
normal  karyotype.  Both of  them received thrombotic  prophylaxis  with LMWH. In these 2 cases,
platelet count levels were stable. But in the first case, fibrinogen level was 3.3 g/L at baseline and
decreased to 1.3 g/l during steroids when the diagnosis of CNS thrombosis was made, without FFP or
fibrinogen supplementation. In the second case, fibrinogen levels were stable > 3 g/L. These 2 patients
experienced headaches, without any other neurological modifications. CT brain showed thrombosis in
the intern jugular vein, which extended in both sigmoid and lateral sinuses, without hemorrhagic intra-
cerebral complications. The 2 patients received curative anticoagulation with UFH, with a complete
resolution of thrombosis and without long-term sequelae. According to the physician’s choice, L-ASP
was not initiated in the patient with CNS thrombosis occurring at Day 2, despite a complete resolution
of symptoms. In the remaining patient, whose CNS thrombosis occurred during the steroid prephase
despite a curative anticoagulation with UFH started since Day -12, all eight L-ASP infusions were
administered,  even though 2 others thrombotic events (sub-clavicular thrombosis and CVC-related
thrombosis) were experienced without any CNS thrombotic recurrence. To date, these 2 patients are
still alive and in CR with OS of 71.8 and 80.9 months respectively.
Discussion
This study involving adult patients treated for ALL or LL aimed to evaluate the prevalence of cerebral
venous thrombosis during induction courses with L-ASP, analyze clinical evolution, and discuss the
management of asparaginase-associated CNS thrombosis. We report here a unique cohort of 20 CNS
thrombosis occurring in adult ALL/LL during induction with L-ASP. However, thrombotic risk factors,
especially hereditary thrombotic risk factors, were not prospectively evaluated in all patients without
CNS thrombosis, limiting the power of this study to detect significant prothrombotic association.
In the GRAALL experience, CNS thrombosis occurred in 3.1% of adult patients during ALL induction
therapy. This is higher than the 1 to 2% incidence rate reported in children,  2,17,18,19 but close to the
2.3% incidence  observed  during  induction  in  214 adults  from the  CAPELAL trial16 or  the  4.3%
incidence  recorded  in  47  adults  patients  treated  at  the  Dana  Farber  Cancer  Institute. 20 Such  a
significant  association between increased age and L-ASP-induced thrombosis has  been previously
reported.20,21 Grace et al recently reported that age was the only significant predictor factor of venous
thrombotic event, in multivariate analysis.20 
Symptoms of CNS thrombosis (headaches, focal motor or sensory neurological deficiency, convulsive
seizure, or loss of consciousness) were similar to those reported in patients without ALL.4 However, in
our cohort, 50% of patients exhibited prodromal signs--almost exclusively headaches--and headaches
were the only sign of thrombosis for 10% of them. The same frequency (3/20) was reported in a recent
cohort  of  children.19 Therefore,  CT scan,  MRI,  or  MR angiography,  depending on the physician’s
preference,  should  be  performed  in  case  of  persistent  headache  without  obvious  explanation,
especially if the headache is not modifified by a shift in posture and worsens with time.
In our cohort,  the prevalence of genetic  prothrombotic conditions  was not  higher  than in  healthy
individuals,22,23 contrary to the increased prevalence of genetic prothrombotic conditions observed in
CNS thrombosis cases without ALL.24,25 
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None of the acquired, well-established risk factors for CNS thrombosis in the general population were
present in our 20 cases, such as combined oral contraceptive use, obstetrical delivery, head injury,
otitis, mastoiditis, meningitis or inflammatory disease.4 An increased thrombotic risk has already been
reported in T-ALL cases.26 In our cohort, T-cell phenotype was observed in 65% patients in the CNS
thrombosis group while it  represented only 43% of patients without CNS thrombosis.  This higher
incidence of T-cell phenotype and male predominance is related to the inclusion of LL patients in our
cohort, which were more frequently male with T-cell phenotype. In our study, data regarding platelet
counts at diagnosis suggest that platelets are not a major factor for the occurrence of CNS thrombosis
during ALL induction with L-ASP, as well as hyperleucocytosis, as shown in an Italian study where
leucocytes  or platelets  were not  found to increase the risk of  thrombosis.27 Lumbar  puncture  is  a
known risk factor for CNS thrombosis in the general population, as low cerebrospinal fluid pressure
following lumbar puncture causes a downward shift of the brain, with traction on cortical veins and
sinus walls that may induce thrombosis.4 In our study, the 11-day delay between the last intra-thecal
injection and CNS thrombosis occurrence appears too long to consider intra-thecal injection as an
acquired thrombotic risk factor.  However, corticosteroid therapy during the beginning of induction
might increase the risk of thrombosis as previously reported.2,3,28 
Our findings suggest that L-ASP infusion, AT level, and CNS thrombosis are closely related. Indeed,
the AT nadir of 47.5% and CNS thrombosis occurred after a median of 17 and 18 days following the
start of induction therapy, respectively, i.e., 4 days after the third L-ASP infusion. In addition, 83% of
patients  for  whom data  was available  displayed AT <60% the day or  the  day before  thrombosis.
Likewise, in the CAPELAL study, thrombotic events occurred after a median of four (range: 1-6) L-
ASP injections, with a median AT level of 53% at the time of thrombosis.16 In general, AT dosages
were performed by centers prior to each L-ASP infusion (Days 8, 10, 12, and then every two days
from Day 20 to 28), as recommended but were not closely monitored in the time period (Days 13 to
20) without L-ASP infusions. The decreased AT monitoring, and resulting decreased AT substitution,
might  account  for  the  occurrence  of  CNS  thrombosis  around  Day  18.  In  the  CAPELAL study,
prophylactic  replacement  therapy with AT concentrates  was  associated  with  decreased  thrombosis
rates  in  ALL patients  treated  with  L-ASP16  (4.8%  vs 12.2% in  patients  without  AT prophylactic
replacement, p= .04). The PAARKA trial in children showed safety and a trend towards efficacy with
AT concentrates  in  the  prevention  of  thrombosis  but  the  study was  not  powered  to  answer  this
question.29 In our study, AT prophylactic replacement was performed less frequently (45%) in patients
with CNS thrombosis than in patients without CNS thrombosis (83.2%) (p= .0002) suggesting that AT
prophylactic  replacement  might  decrease  the  occurrence  of  CNS  thrombosis  and  we  highly
recommend AT substitution for the future GRAALL2014 protocol.
In line with the CAPELAL study results,16 90% of our patients underwent thrombotic prophylaxis
using  continuous  UFH  infusion  at  100  IU/Kg/day,  which  did  not  prevent  CNS  thrombosis.
Prophylactic LMWH with AT infusion might be a better choice to prevent thrombosis, than a single
prophylactic anticoagulation. Indeed, concomitant treatment with LMWH and AT was associated with
reduced thrombosis rates (0/41) in children with ALL treated with L-ASP, as compared to a historical
control cohort treated with AT alone (9/71, 12.7%) (p= .02)30. 
Finally, the optimal management of CNS thrombosis during ALL induction with L-ASP is not well-
defined. In our cohort, no increased cerebral haemorrhages were reported after heparin treatment with
platelet  transfusion  support.  The  20%  and  5%  poor  neurological  recovery  and  death  cases,
respectively,  were  identical  to  those  reported  in  the  scientific  literature  in  relation  with  CNS
thrombosis in the general population.4 However, no data is available for the use of AT replacement
after thrombosis. Re-exposure to L-ASP after a venous thrombosis occurrence is subject to debate as
L-ASP is  a  major  drug  in  ALL therapy.  Indeed,  in  pediatric  and  adults  patients,  early  L-ASP
discontinuation due to thrombosis was associated with reduced EFS rates.16,20
8
 In  our  study,  1  patient  with  early  CNS  thrombosis  received  8  L-ASP infusions  without  CNS
thrombotic recurrence. Data about L-ASP re-exposure in this context are conflicting. One Indian child
was re-exposed without thrombotic recurrence.31 In the UKALL study, 38 children with thrombosis,
including 10 CNS thrombosis cases, were re-exposed to L-ASP with concurrent heparin administration
with  neither  recurrent  thrombosis  nor  bleeding  complications  observed.17 However  in  the  DFCI
experience, among 33 patients restarted on L-ASP after venous thrombosis, 33% (11/33) experienced a
recurrence of thrombosis, more frequently in adults than in children (47% vs 17%, p= .07). There was
no association between initial site of thrombosis and risk of clot recurrence. 20 Therefore, re-exposure
to L-ASP can probably be performed in the setting of carefully monitored AT and anticoagulation with
heparin or LMWH, provided that venous flow recovery is observed on CT scan or angioMRI but
further studies are warranted to clarify this issue. 
In conclusion, CNS thrombosis is a significant complication of ALL therapy in adults. Our findings
suggest a predilection for this event in young male patients with T-ALL and LL treated as ALL -
attributable neither to IT nor to thrombophilia - and an association with low-level AT that strengthens
the causal link with L-ASP. However, L-ASP is a major drug in ALL therapy and the discontinuation
of  this  drug  might  be  detrimental  to  patients.  AT  concentrate  replacement,  heparin-based
antithrombotic prophylaxis and L-ASP re-exposure still needs to be evaluated. 
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Figure 1: Kaplan-Meier overall survival curves in patients with and without central nervous 
system venous (CNS) thrombosis. 
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Table I: Characteristics of the 706 patients with and without CNS thrombosis. 
WBC: white blood cell count, BMI: body mass index, CNS: central nervous system, L-ASP: L-asparaginase, IT: intra-thecal injection, AT: antithrombin, FFP: 
fresh frozen plasma, LMWH: low molecular weight heparin, UFH: unfractionated heparin, OS: overall survival, DFS: disease-free survival.
Number of patients
(available data)
CNS-Thrombosis
n=20
No CNS-thrombosis
n=686 p
Median of age (years) 706 29 33 .447
Number of male patients 706 15 (75%) 434 (63.3%) .283
T-cell phenotype 705 13 (65%) 296 (43.2%) .053
WBC > 30.109/L at diagnosis 706 5 (25%) 188 (27.5%) .806
CNS involvement 706 1 (5%) 38 (5.9%) .917
BMI 563 23 23 (n=540) .839
Protocols type 
- GRAALL2003
- GRAALL2005
- LL03
225
346
135
2
13
5
223
333
130
.104
Median number of L-ASP infusions 696 3 7 < .001
Median number of IT 350 3 2 < .001
Platelet level at diagnosis (109/L) 482 91 123.5 .897
Fibrinogen level at diagnosis (g/L) 672 3,3 4 .149
Median AT nadir 327 47.5 51 .25
Median number of FFP 292 0 0 .83
Median number of fibrinogen infusions 318 0 0 .848
AT prophylaxis 353 9 (45%) 277 (83.2%) .0002
Heparin (LMWH/UFH) prophylaxis 268 18 (90%) 161 (64.9%) .025
3-year overall survival (%) 706 55 75.9 .399
3-years disease-free survival (%) 611 61.3 79.5 .182
Pt Prodromalsymptoms Thrombosis symptoms Site of thrombosis
Hemorrhagic
associated
Other
thrombosis
AT
Curative 
Curative
anticoagulant
T-
Evolution
1 no deficit, seizure lateral, longitudinal no PE, leg T no UFH no
2 headaches deficit, seizure cortical veins yes leg T yes LMWH sequelae
3 headaches deficit lateral, longitudinal yes no yes UFH sequelae
4 no deficit, seizure sagittal, cortical no no no UFH no
5 no deficit, seizure cortical, longitudinal no no no LMWH no
6 no deficit, seizure cortical veins no no yes LMWH sequelae
7 no headaches, deficit lateral, longitudinal, cortical no no yes UFH then LMWH no
8 headaches deficit, OPH tb lateral, longitudinal yes no no UFH then LMWH no
9 headaches headaches sagittal sup no PE yes UFH no
10 headaches headaches, deficit,  seizure lateral, longitudinal no no no UFH no
11 headaches headaches cortical veins no no yes UFH no
12 no deficit longitudinal sup no no yes UFH then LMWH no
13 no seizure cortical, longitudinal no no no UFH then LMWH no
14 no deficit, seizure cortical, longitudinal yes no yes UFH no
15 headaches headaches, deficit, seizure longitudinal sup, transverse yes no yes UFH then LMWH sequelae
16 UL paresthesia headaches, deficit, seizure sagittal sup, longitudinal yes PE, leg T no UFH no
17 no headaches, OPH tb sagittal sup, transverse no no no UFH then LMWH no
18 headaches headaches, seizure cortical veins no no no UFH then LMWH no
19 no deficit, seizure cortical veins yes no no - death
20 headaches seizure cortical veins no no no UFH no
Table II: Prodromal symptoms, diagnosis, treatment, and evolution of CNS thrombosis
PE: pulmonary embolism, T: thrombosis, UFH: unfractionated continuous infusion heparin, LMWH: low molecular weight heparin., UL paresthesia: upper 
limb paresthesia, OPH tb: ophtalmic troubles, AT Curative : curative antithrombin infusion, T-Evolution: evolution of thrombosis (sequelae).
Pt Age Sex Phenotype High doseCPM CNS+
WBC
> 30 G/L BMI
Day of
CNS T
Nb of L-ASP
before T
Nb of IT
before T
Heparin
prophylaxis
Day of AT Nadir
(AT Nadir level)
AT level
d-1/d0
before T
AT infusion
prophylaxis
1 43 M T-ALL no no no 27.4 17 3 2 UFH 16 (45%) 45% yes
2 42 M B-ALL no no no 28.7 19 3 3 no 18 (58%) 58% no
3 46 F B-ALL yes no no 20.7 22 4 3 UFH 24 (36%) 43% no
4 18 M T-LL yes no no 29.5 14 2 3 no 17 (55%) 65% no
5 27 M T-LL no no no 23.6 21 4 3 UFH 12 (39%) N/A yes
6 38 F T-ALL yes no yes 20.4 25 6 2 UFH 25 (50%) 50% no
7 24 M T-LL no no no 21 16 3 3 UFH 26 (47%) N/A no
8 26 M B-ALL yes no yes 21.9 31 7 3 UFH 22 (43%) N/A yes
9 19 F T-LL no no no 25.5 20 4 2 UFH 13 (56%) N/A yes
10 41 M B-ALL no no yes 22 18 3 3 UFH 14 (67%) N/A no
11 42 F B-ALL yes no yes 21.9 24 6 3 UFH 28 (41%) 56% yes
12 27 M T-ALL yes no no 20.2 18 3 3 UFH 18 (42%) 41% no
13 22 M B-ALL no no yes 23.9 21 4 3 UFH 21 (52%) 52% yes
14 37 F T-ALL no no no 20.4 17 3 3 UFH 18 (43%) N/A no
15 40 M T-ALL yes no no 24.9 11 3 1 UFH 13 (47%) 58% yes
16 23 M T-ALL yes yes yes 23.3 14 3 3 UFH 16 (50%) 78% yes
17 20 M T-ALL yes no no 18.7 19 3 3 UFH 17 (48%) 51% yes
18 23 M T-ALL yes yes yes 23 17 2 4 UFH 20 (59%) N/A no
19 50 M T-ALL no no no 24.9 12 3 3 UFH 12 (49%) N/A yes
20 31 M B-ALL no no no 23.3 15 3 2 UFH 3 (46%) 49% no
Table III: Characteristics of patients and AT evolution
Pt: patient, CPM: cyclophosphamide, CNS +: blastic CNS involvement, BMI: body mass index, T: thrombosis, Nb: number, IT: intrathecal injection, UFH: 
unfractionated continuous infusion heparin, N/A: data not available.
